| Lightcalls.com |
|
|
![]() |
Complaints about directors are rela...Complaints about directors are relatively rare, on the contrary this doesn't mean directors have anything les to worry about-it simply deliberates our members' employment and the aggregation of risks in dealing with numerous clients. This fictionalized account involving a director is based loosely forward an actual case before the Professional bearing Enquiry Committee (PCEC). Names and circumstances have been changed to secure anonymity. The situation After 35 years in public practice, CA Tim retired. Eager to detain working, he began consulting and serving in succession several boards. A former partner presently introduced him to the directors of Newco who invited him to join their board. Newco which had already planned to move public, subsequently put out couple offering memoranda and raised almost $2 million. however six months after joining the board, Tim resigned, having conclud that Newco would not be able to encounter its commitments and fund its start-up period. He felt relieved to avoid what he saw coming next-impossible squeezing to keep Newco in operation. What happened Shortly after Tim's resignation, the provincial regulator began investigating Newco Everyone cooperated completely with the investigation except Jake-Newco's planter CEO, and largest shareholder. The regulator ultimately determined that Jake had withheld information from the other directors-deliberately misleading them, the auditors, and Newco's legal suggestion and not disclosing the fact that near significant transactions had not been made at arm's length When the regulator filed its notice of hearing, Tim was outraged to find himself included among the other directors. He engaged opinion At first he was absolutely convinced that he'd done nothing wrong; however, by the and of consultations with his lawyer, he shortly came to have a broader understanding of the duties of a director, particularly single in kind who is a signatory to corporate filings. As an auditor, Tim had understood that management representations required appropriate questioning. This continual proces of enquiry, discussion, and assessment had always been an automatic part of his assurance work. for a like reason why hadn't he used this long-standing habit as a director? Tim believed the introduction to Newco's directors at his former partner combined with the change from auditor to director had apted him to relax his guard. Lookine back, he realized he hadn't taken the time to think critically about his recent duties and, most importantly, hadnt taken the time to check disclosed his new associates. Knowing he could not fortunately defend himself against all of the regulator's allegations, and aware of the expenses of a hearing, Tim accepted a reconciliation agreement. The agreement included payment of a fine and expenses and an eight-year prohibition against acting as an officer or director of a public company, or relying in succession exemptions provided by securities legislation. Tim signed the pacification agreement and thought his concerns were over. He was wrong The outcome Tim disesteemed to inform the Institute of his arrangement agreement, but since the regulator automatically advises the Institute of notices concerning any ICABC member, word shortly got to the PCEC anyway. Tim got a literal sense advising him of the PCEC investigation around the same time as the local newspaper published a story about Newco and Tim's involvement as a director. Tim denied awareness of his obligation to advise the Institute, and admitted that he hadn't considered the damage to the profession as he negotiated the adjustment He also admitted that he hadn't agreed with all of the regulators conclusions, believing that more [i]or[/i] less of the expectations went beyond what could have been reasonably calculate uponed in the circumstances. He did, however, agree that in an cases he should have been more careful and more sceptical about accepting representations from Jake. The PCEC agreed that an of the allegations were too far-reaching, moreover agreed that others were valid. As a terminate the PCEC determined that Tim had breached direction 102.1 (Reporting Criminal or Similar Offences) through not notifying the Institute promptly of the adjustment agreement; Rule 201.1 (Maintenance of Reputation of the Profession); sway 205(a) (False and Misleading Documents) because there were omissions and misstatements in the Newco offering memoranda; and mastership 213 (Unlawful Activity) because his inaction had breached securities and companies legislation. The PCEC conclud that the regulator had adequately guarded the public interest and furnished Tim a determination and recommendation. Tim accepted an anonymous reprimand and paid a significant fine and costs The message The strange Rule 206 will require any CA who sits forward a board of directors to use the professional skills and knowledge of a capable CA. Being a director can be real rewarding, but it does carry a number of significant risks. Before taking forward a directorship, apply your to be ascribed diligence to your fellow directors and officers. Use the professional scepticism you've bring outed as a CA. Check disclosed critical matters for yourself. |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |